Episodes 16-30 of 845
Real-World Impact of Evolocumab on MACE Reduction in ASCVD
CardiologyReal-World Impact of Evolocumab on MACE Reduction in ASCVD
Global Burden of Stroke and Myocardial Infarction in Patients at High Risk of First MACE: Insights From the VESALIUS-REAL Study
CardiologyGlobal Burden of Stroke and Myocardial Infarction in Patients at High Risk of First MACE: Insights From the VESALIUS-REAL Study
Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke: Primary Results of the VESALIUS-CV Trial
CardiologyEvolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke: Primary Results of the VESALIUS-CV Trial
Finerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
NephrologyFinerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
Implications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
NephrologyImplications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
New Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
NephrologyNew Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
- advertisement
The Impact of Finerenone Plus Empagliflozin on Hyperkalemia in the CONFIDENCE Trial
NephrologyThe Impact of Finerenone Plus Empagliflozin on Hyperkalemia in the CONFIDENCE Trial
PREVENT vs PCE: Refining ASCVD Risk Prediction in Statin-Treated Populations
Heart MattersPREVENT vs PCE: Refining ASCVD Risk Prediction in Statin-Treated Populations
The LDL-C Gap in Statin-Treated Patients: A Population-Level Problem with Economic Consequences
Heart MattersThe LDL-C Gap in Statin-Treated Patients: A Population-Level Problem with Economic Consequences
Reframing Monotherapy and Combination Strategies for Hyperlipidemia
Heart MattersReframing Monotherapy and Combination Strategies for Hyperlipidemia
Understanding Preload Deficiency in SLE: A New Look at Fatigue and Exercise Intolerance
Living RheumUnderstanding Preload Deficiency in SLE: A New Look at Fatigue and Exercise Intolerance
Managing Genotype-Positive Patients in Hereditary ATTR-CM
On the Frontlines of ATTR-CMManaging Genotype-Positive Patients in Hereditary ATTR-CM
- advertisement
The Cost of Progress: Examining Barriers to ATTR-CM Care
On the Frontlines of ATTR-CMThe Cost of Progress: Examining Barriers to ATTR-CM Care
Understanding Lipid and Lipoprotein Metabolism in Cardiovascular Health
Heart MattersUnderstanding Lipid and Lipoprotein Metabolism in Cardiovascular Health
How Systemic Psoriasis Therapies Influence the Risk of New or Recurrent MACEs
FCDC Action CenterHow Systemic Psoriasis Therapies Influence the Risk of New or Recurrent MACEs
